Our study indicates that targeting RBM39 in combination with anti-GD2 therapy may eradicate neuroblastoma cells irrespective of their cell state switching potential, providing a rationale to combine indisulam and anti-GD2 mAb as a therapy for high-risk neuroblastoma patients. The gene discussed is RBM39; the disease is neuroblastoma.